Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman Sells 2,274 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman sold 2,274 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $118.37, for a total value of $269,173.38. Following the transaction, the director now owns 519,074 shares in the company, valued at approximately $61,442,789.38. This trade represents a 0.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Kevin Charles Gorman also recently made the following trade(s):

• On Friday, January 31st, Kevin Charles Gorman sold 2,707 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $152.92, for a total value of $413,954.44.
• On Monday, January 27th, Kevin Charles Gorman sold 146,105 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $149.46, for a total transaction of $21,836,853.30.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock traded up $0.33 during midday trading on Wednesday, reaching $117.18. 2,148,807 shares of the stock were exchanged, compared to its average volume of 1,350,825. The company’s fifty day moving average is $138.49 and its 200-day moving average is $131.02. The firm has a market cap of $11.86 billion, a PE ratio of 35.62 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. On average, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors have recently made changes to their positions in the business. ExodusPoint Capital Management LP purchased a new stake in Neurocrine Biosciences during the 4th quarter valued at $2,163,000. Motley Fool Asset Management LLC boosted its position in Neurocrine Biosciences by 10.8% during the 4th quarter. Motley Fool Asset Management LLC now owns 2,249 shares of the company’s stock valued at $307,000 after buying an additional 220 shares during the period. Westpac Banking Corp boosted its position in Neurocrine Biosciences by 11.4% during the 4th quarter. Westpac Banking Corp now owns 13,989 shares of the company’s stock valued at $1,909,000 after buying an additional 1,429 shares during the period. Cinctive Capital Management LP purchased a new stake in Neurocrine Biosciences during the 4th quarter valued at $2,234,000. Finally, Huntington National Bank lifted its position in shares of Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company’s stock worth $31,000 after purchasing an additional 97 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

NBIX has been the subject of a number of research reports. Piper Sandler reissued an “overweight” rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Barclays raised their price target on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a report on Monday, December 23rd. Guggenheim lowered their price target on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating for the company in a report on Monday. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Finally, StockNews.com raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Monday. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $166.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.